Email

weborders@prabadincorp.com

Call us

+1 (786)-332-3938
administrator
chpt-co-founder-outlines-new-ai-strategies-to-tackle-challenges-and-seize-growth-opportunities-in-taiwan’s-semiconductor-market. Medical Supplies
  • January 30, 2025

CHPT co-founder outlines new AI strategies to tackle challenges and seize growth opportunities in Taiwan’s semiconductor market.

The semiconductor industry is swiftly advancing due to high-performance computing and AI smartphones, creating opportunities for AI semiconductors. With the…
chinese-automakers-face-challenges-in-auto-parts-localization-amid-quality-demands Medical Supplies
  • January 30, 2025

Chinese automakers face challenges in auto parts localization amid quality demands

The automotive industry’s stringent safety and reliability requirements are presenting significant challenges to the Chinese government’s ongoing push to increase…
ai-robots-emerge-as-new-competitive-frontier-for-automakers Medical Supplies
  • January 30, 2025

AI robots emerge as new competitive frontier for automakers

The convergence of AI robotics and automotive manufacturing presents a critical turning point for the industry. As automakers explore artificial…
fda-approves-novel-non-opioid-treatment-for-moderate-to-severe-acute-pain Drug Test
  • January 30, 2025

FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

The FDA approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic to treat moderate to severe acute pain…
drug-trials-snapshots:-bimzelx Drug Test
  • January 30, 2025

Drug Trials Snapshots: BIMZELX

BIMZELX is an anti-interleukin (IL)-17A and IL-17F monoclonal antibody that is indicated for the treatment of adults with moderate to…
drug-trials-snapshot:-livtencity Drug Test
  • January 30, 2025

Drug Trials Snapshot: LIVTENCITY

LIVTENCITY is a prescription medicine used to treat cytomegalovirus (CMV) infection and disease.
drug-trials-snapshots:-leqselvi Drug Test
  • January 30, 2025

Drug Trials Snapshots: LEQSELVI

LEQSELVI is a Janus kinase (JAK) inhibitor that is indicated for the treatment of adults with severe alopecia areata (AA).
drug-trials-snapshot:-nexviazyme Drug Test
  • January 30, 2025

Drug Trials Snapshot: NEXVIAZYME

NEXVIAZYME is an enzyme used for the treatment of patients 1 year of age and older with late-onset Pompe disease…
fda-drug-safety-communication:-update-on-tumor-necrosis-factor-(tnf)-blockers-and-risk-for-pediatric-malignancy Drug Test
  • January 30, 2025

FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy

[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis…
spotlight-on-cder-science Drug Test
  • January 30, 2025

Spotlight on CDER Science

FDA scientists carry out laboratory, clinical and analytical research to address knowledge gaps in drug development, healthcare technologies and post-market…